ArticleMolecular therapy : the journal of the American Society of Gene Therapy2017
Targeting of Aberrant αvβ6 Integrin Expression in Solid Tumors Using Chimeric Antigen Receptor-Engineered T Cells.
Article in Molecular therapy : the journal of the American Society of Gene Therapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 52 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 75 citations in OpenAlex.
- Comparison of theMolecular therapy. Oncology · 2026Article
- Optimization of a parallel CAR for B-cell lymphoma via ITAM attenuation and target specificity validation.Clinical and experimental immunology · 2026Article
- Engineered natural killer cells for cancer therapy.Cancer cell · 2025Review
- Integrin α6 Targeted Tumor Theranostics.Phenomics (Cham, Switzerland) · 2025Review
- Article
- Mechanisms of antigen-dependent resistance to chimeric antigen receptor (CAR)-T cell therapies.Cancer cell international · 2025Review
- Solid tumor immunotherapy using NKG2D-based adaptor CAR T cells.Cell reports. Medicine · 2024Article
- Granzyme B-activated IL18 potentiates αβ and γδ CAR T cell immunotherapy in a tumor-dependent manner.Molecular therapy : the journal of the American Society of Gene Therapy · 2024Article
- Car T Cells in Solid Tumors: Overcoming Obstacles.International journal of molecular sciences · 2024Review
- Article
- CAR-based immunotherapy for breast cancer: peculiarities, ongoing investigations, and future strategies.Frontiers in immunology · 2024Review
- Article
- Oncolytic virus and CAR-T cell therapy in solid tumors.Frontiers in immunology · 2024Review
- Structural analysis of peptide binding to integrins for cancer detection and treatment.Biophysical reviews · 2023Review
- The Interplay between Integrins and Immune Cells as a Regulator in Cancer Immunology.International journal of molecular sciences · 2023Review
- Review
- Current updates on generations, approvals, and clinical trials of CAR T-cell therapy.Human vaccines & immunotherapeutics · 2022Article
- Immunotherapy and immunoengineering for breast cancer; a comprehensive insight into CAR-T cell therapy advancements, challenges and prospects.Cellular oncology (Dordrecht, Netherlands) · 2022Review
- Article
- Generation of human parallel chimeric antigen receptor (pCAR) T cells to achieve synergistic T cell co-stimulation.STAR protocols · 2022Article
Corrections and comments
- Erratum issued
- Erratum issued
Authors and funding
15 authors at 7 institutions in 3 countries.
Funding
Abstract
Expression of the αvβ6 integrin is upregulated in several solid tumors. In contrast, physiologic expression of this epithelial-specific integrin is restricted to development and epithelial re-modeling. Here, we describe, for the first time, the development of a chimeric antigen receptor (CAR) that couples the recognition of this integrin to the delivery of potent therapeutic activity in a diverse repertoire of solid tumor models. Highly selective targeting αvβ6 was achieved using a foot and mouth disease virus-derived A20 peptide, coupled to a fused CD28
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.